Dispensing issues and disciplinary measures during opioid agonist treatment: A viewpoint

Arnab Datta; Siddharth Sarkar

doi:10.5055/jom.0922

Authors

Arnab Datta, MD https://orcid.org/0009-0003-3544-5528
Siddharth Sarkar, MD

DOI:

https://doi.org/10.5055/jom.0922

Keywords:

opioid agonist therapy, dispensing, disciplinary measures

Abstract

Opioid Use Disorder (OUD) poses a significant public health challenge globally, with an estimated 23 million opioid users in India. Opioid Agonist Therapy (OAT) stands as the cornerstone of treatment, offering potential reductions in morbidity, societal burdens, and improvements in patient quality of life. However, OAT coverage remains fairly low in India, with clinical guidelines lacking comprehensive information on implementation pragmatics. This viewpoint delves into the nuanced challenges faced by clinicians in the daily operations of OAT emphasizing disciplinary issues, practical responses, and the broader implications for treatment outcomes and public perception. The treatment provider’s response is explored from different aspects like learning theory, attitude, psychodynamic interactions, and ethics. Understanding patient perspectives, including employment demands and perceptions of fairness, is crucial in tailoring responses and optimizing treatment engagement. While disciplinary measures are integral to maintaining treatment sanctity, their effectiveness must be balanced with patient autonomy and harm reduction goals. The discourse surrounding OAT disciplinary measures necessitates a multifaceted approach, integrating evidence-based practices, clinician experiences, patient rights, and administrative considerations to ensure equitable and effective treatment provision.

Author Biographies

Arnab Datta, MD

Senior Resident, Department of Psychiatry and National Drug Dependence Treatment Center, All India Institute of Medical Sciences, New Delhi

Siddharth Sarkar, MD

Additional Professor, National Drug Dependence Treatment Center, All India Institute of Medical Sciences, New Delhi

References

Institute for Health Metrics and Evaluation (IHME): Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 2018. Available at https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf. Accessed January 14, 2025.

Ambekar A, Agarwal A, Rao R, et al.: Magnitude of Substance Use in India 2019. National Survey on Extent and Pattern of Substance Use in India. New Dehli: Ministry of Social Justice and Empowerment, Government of India. Available at https://online.fliphtml5.com/ljdmb/aacc/. Accessed April 29, 2024.

Connock M, Juarez-Garcia A, Jowett S, et al.: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess Winch Engl. 2007; 11(9): 1-171, iii-iv. DOI:10.3310/hta11090.

Gisev N, Bharat C, Larney S, et al.: The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. Lancet Public Health. 2019; 4(7): e334-e342. DOI:10.1016/S2468-2667(19)30060-X.

Salsitz EA, Joseph H, Frank B, et al.: Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice–a summary report (1983-1998). Mt Sinai J Med NY. 2000; 67(5-6): 388-397.

Colledge-Frisby S, Ottaviano S, Webb P, et al.: Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023; 11(5): e673-e683. DOI:10.1016/S2214-109X(23)00058-X.

Stitzer M, Bigelow G: Contingency management in a methadone maintenance program: availability of reinforcers. Int J Addict. 1978; 13(5): 737-746. DOI:10.3109/10826087809039299.

Harris MTH, Lambert AM, Maschke AD, et al.: “No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Subst Abuse Treat. 2022; 135: 108655. DOI:10.1016/j.jsat.2021.108655.

Krawczyk N, Rivera BD, Levin E, et al.: Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. Lancet Public Health. 2023; 8(3): e238-e246. DOI:10.1016/S2468-2667(23)00023-3.

Anstice S, Strike CJ, Brands B: Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009; 44(6): 794-808. DOI:10.1080/10826080802483936.

Madden EF, Christian BT, Lagisetty PA, et al.: Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021; 228: 109100. DOI:10.1016/j.drugalcdep.2021.109100.

Math SB, Mohan A, Kumar NC: Opioid substitution therapy: Legal challenges. Indian J Psychiatry. 2018; 60(3): 271. DOI:10.4103/psychiatry.IndianJPsychiatry_391_18.

Madden EF: Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med 1982. 2019; 232: 324-331. DOI:10.1016/j.socscimed.2019.05.027.

Peles E, Schreiber S, Sason A, et al.: Earning “Take-Home” Privileges and Long-Term Outcome in a Methadone Maintenance Treatment Program. J Addict Med. 2011; 5(2): 92. DOI:10.1097/ADM.0b013e3181e6ad48.

Verma M, Vijayakrishnan A: Psychoanalytic psychotherapy in addictive disorders. Indian J Psychiatry. 2018; 60(Suppl 4): S485-S489. DOI:10.4103/psychiatry.IndianJPsychiatry_16_18.

Stitzer ML, Bigelow GE, McCaul ME: Behavior therapy in drug abuse treatment: review and evaluation. NIDA Res Monogr. 1985; 58: 31-50.

Gerra G, Saenz E, Busse A, et al.: Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(2): 483-489. DOI:10.1016/j.pnpbp.2010.12.002.

Kathiresan P, Patel V, Jangra J, et al.: Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India. Asian J Psychiatry. 2024; 95: 103979. DOI:10.1016/j.ajp.2024.103979.

Gomes T, Campbell TJ, Kitchen SA, et al.: Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022; 327(9): 846-855. DOI:10.1001/jama.2022.1271.

Williams AR, Krawczyk N, Hu MC, et al. Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study. Lancet Reg Health - Am. 2023; 28: 100636. DOI:10.1016/j.lana.2023.100636.